Clinical Trial Update: Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing neoadjuvant therapy with pyrotinib, trastuzumab, pertuzumab, and nab-paclitaxel for HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Pertuzumab (pertuzumab)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Breast Cancer Invasive | Phase 2 | Status: ACTIVE_NOT_RECRUITING